Trader consensus on Polymarket reflects razor-thin implied probabilities across Encore Medical's IPO closing market cap outcomes, driven by terms set December 2025 for 3 million shares at $5 on NYSE American—implying a $48.7 million fully diluted valuation amid $1.88 million trailing twelve-month revenue and $1.23 million net loss. The closely contested odds stem from uncertainty in final pricing adjustments, first-day trading pop or discount, and minor postponement risk before June 2026 resolution, given tepid medtech IPO demand and broader biotech volatility. Key swing factors include roadshow reception highlighting CE-marked septal occluders with 35,000 ex-U.S. implants versus pending FDA pivotal trial funding needs; pricing announcement imminent ahead of April 15 launch.
Résumé expérimental généré par IA à partir des données Polymarket · Mis à jourEncore Medical IPO Closing Market Cap
Encore Medical IPO Closing Market Cap
45M–50M 49%
55M+ 49%
No IPO before June 2026 49%
<45M 49%
NOUVEAU
NOUVEAU
15 avr. 2026
<45M
49%
45M–50M
49%
50M–55M
49%
55M+
49%
No IPO before June 2026
49%
45M–50M 49%
55M+ 49%
No IPO before June 2026 49%
<45M 49%
NOUVEAU
NOUVEAU
15 avr. 2026
<45M
$0 Vol.
49%
45M–50M
$1 Vol.
49%
50M–55M
$1 Vol.
49%
55M+
$0 Vol.
49%
No IPO before June 2026
$0 Vol.
49%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket reflects razor-thin implied probabilities across Encore Medical's IPO closing market cap outcomes, driven by terms set December 2025 for 3 million shares at $5 on NYSE American—implying a $48.7 million fully diluted valuation amid $1.88 million trailing twelve-month revenue and $1.23 million net loss. The closely contested odds stem from uncertainty in final pricing adjustments, first-day trading pop or discount, and minor postponement risk before June 2026 resolution, given tepid medtech IPO demand and broader biotech volatility. Key swing factors include roadshow reception highlighting CE-marked septal occluders with 35,000 ex-U.S. implants versus pending FDA pivotal trial funding needs; pricing announcement imminent ahead of April 15 launch.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Marché ouvert : Apr 3, 2026, 7:59 PM ET
Volume
$2Date de fin
15 avr. 2026Marché ouvert
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader consensus on Polymarket reflects razor-thin implied probabilities across Encore Medical's IPO closing market cap outcomes, driven by terms set December 2025 for 3 million shares at $5 on NYSE American—implying a $48.7 million fully diluted valuation amid $1.88 million trailing twelve-month revenue and $1.23 million net loss. The closely contested odds stem from uncertainty in final pricing adjustments, first-day trading pop or discount, and minor postponement risk before June 2026 resolution, given tepid medtech IPO demand and broader biotech volatility. Key swing factors include roadshow reception highlighting CE-marked septal occluders with 35,000 ex-U.S. implants versus pending FDA pivotal trial funding needs; pricing announcement imminent ahead of April 15 launch.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 15 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$2Date de fin
15 avr. 2026Marché ouvert
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader consensus on Polymarket reflects razor-thin implied probabilities across Encore Medical's IPO closing market cap outcomes, driven by terms set December 2025 for 3 million shares at $5 on NYSE American—implying a $48.7 million fully diluted valuation amid $1.88 million trailing twelve-month revenue and $1.23 million net loss. The closely contested odds stem from uncertainty in final pricing adjustments, first-day trading pop or discount, and minor postponement risk before June 2026 resolution, given tepid medtech IPO demand and broader biotech volatility. Key swing factors include roadshow reception highlighting CE-marked septal occluders with 35,000 ex-U.S. implants versus pending FDA pivotal trial funding needs; pricing announcement imminent ahead of April 15 launch.
Résumé expérimental généré par IA à partir des données Polymarket · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes